Business
AC Immune Initiates Phase 1 Clinical Trial of NLRP3 Inhibitor
AC Immune Initiates Phase 1 Clinical Trial of NLRP3 Inhibitor ACI-19764 is an orally available highly brain-penetrant small molecule NLRP3 inhibitorNLRP3
About this update from Ac Immune Sa
[{"type":"text","content":"AC Immune Initiates Phase 1 Clinical Trial of NLRP3 Inhibitor ACI-19764 is an orally available highly brain-penetrant small molecule NLRP3 inhibitorNLRP3 inhibitors are a major new class of compounds linked to a broad spectrum of inflammatory conditions including both metabolic and neurological diseasesACI-19764 is an important addition to AC Immune’s growing small molecule pipelinePhase 1 results in healthy volunteers are expected in H2 2026 Lausanne, Switzerland, February 24, 2026 -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announced that the first participant has been dosed in a Phase 1 clinical trial of ACI-19764, an orally administered small molecule inhibitor of the NLRP3 inflammasome. Targeting the NLRP3 inflammasome provides an opportunity to reduce the chronic inflammation thought to be associated with disease progression in multiple inflammatory disorders, metabolic diseases, and neurological diseases, including Alzheimer’s disease (AD), Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS) and frontotemporal dementia. Dr. Andrea Pfeifer, CEO of AC Immune SA, commented: \"We are delighted to announce the dosing of the first participant in the Phase 1 trial in healthy volunteers of our lead NLRP3 inhibitor. This is another important milestone in demonstrating the power of AC Immune’s small molecule discovery capabilities for targeting key pathways that contribute to neurodegeneration and other diseases. Robust preclinical data have shown that ACI-19764 has best-in-class potential based on its potency and PK profile, as well as its ability to reduce neuroinflammation and limit neurodegeneration in vivo. This suggests ACI-19764 could have a disease-modifying effect relevant to neurodegenerative diseases, and we are looking forward to studying it further in the clinical setting.” The Phase 1 trial will investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ACI-19764 in healthy volunteers. The study is divided into two parts. Part A will evaluate single ascending doses while Part B will examine multiple ascending doses. The trial is being conducted in Europe. Primary outcome measures include the safety and tolerability of ACI-19764, as well as its pharmacokinetics in plasma and cerebrospina...